Join
Live feed
·
PRReleasevia Quantisnow
TScan Therapeutics Inc. logo

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

ByQuantisnow·Wall Street's wire, on your screen.
TCRX· TScan Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TCRX (TScan Therapeutics Inc.) and more on Quantisnow.